| Name | Title | Contact Details |
|---|
Generation after generation, families have depended upon Silver Cross Hospital to care for their loved ones. The commitment goes back to Thanksgiving Day in 1895 when the Will County Union of King`s Daughters and Sons opened the doors of a 33-bed hospital in Joliet named after their emblem the Maltese cross. Their promise was to provide quality healthcare with compassion for the citizens of Will County and surrounding communities. Today, more than a century later, Silver Cross Hospital remains true to that original promise. As the needs of the community grew, so did Silver Cross—in size and stature. Services rapidly expanded, evolved and increased in complexity. The medical staff advanced superior healthcare and attracted new expertise including specialists with Ann & Robert H. Lurie Children`s Hospital of Chicago, The Rehabilitation Institute of Chicago (RIC), University of Chicago Medicine Comprehensive Cancer Center, Northwestern Medicine for neurosciences and stroke care, and the Midwest Institute for Robotic Surgery. Silver Cross performs more robotic-assisted procedures than any other facility in the Chicago area. Surgeons from around the world come train with us. National prominence was achieved when Silver Cross- an independent healthcare provider, was first recognized as one of the nation`s 100 Top Hospitals in 2004—an accomplishment that has been repeated for seven years. And year after year, Silver Cross has been acknowledged as one of American`s Friendliest Hospitals because we treat patients the way they should be treated and for our dedication to patient safety with an “A” Hospital Safety Score from the Leapfrog Group. The mission of providing quality healthcare continues today with a remarkable 296-bed replacement hospital, which opened in 2012. All patient rooms are private—accommodating today`s medical technology and ultimately reducing unnecessary transfers and the risk of infection and injury. The hospital`s unique design creates efficiencies between departments and promotes an environment that helps patients heal faster. Our 158-acre New Lenox campus includes three medical/office buildings, University of Chicago Medicine Comprehensive Cancer Center, and an ambulatory care center opening in fall 2017. The hospital also has plans to build a 100-bed Behavioral Health Hospital to open in 2019. Over the years, Silver Cross has developed an extensive ambulatory network throughout the region that includes five satellite facilities with the independent services of many physicians and an array of outpatient services such as diagnostic imaging and rehabilitation. Silver Cross also operates a 27/7 freestanding Emergency Care Center in Homer Glen and an Urgent Care center in Joliet.
Nuvisan Pharma Services is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
24Hr HomeCare is a El Segundo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Heritage At Falmouth is a Falmouth, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.